Longitudinal CSF and MRI biomarkers improve the diagnosis of mild cognitive impairment
Authors:
- M.J. de LeonMLM.J. de Leon
- S. DeSantiSDS. DeSanti
- R. ZinkowskiRZR. Zinkowski
- P.D. MehtaPMP.D. Mehta
- D. PraticoDPD. Pratico
- S. SegalSSS. Segal
- H. RusinekHRH. Rusinek
- J. LiJLJ. Li
- W. TsuiWTW. Tsui
- L.A. Saint LouisLLL.A. Saint Louis
- C.M. ClarkCCC.M. Clark
- C. TarshishCTC. Tarshish
- 1 March 2006
- journal article
- research article
- Published by Elsevier in Neurobiology of Aging
- Vol. 27 (3) , 394-401
Abstract
No abstract availableKeywords
This publication has 37 references indexed in Scilit:
- CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairmentNeurology, 2005
- Value of CSF β-amyloid1–42 and tau as predictors of Alzheimer's disease in patients with mild cognitive impairmentMolecular Psychiatry, 2003
- Biological markers for therapeutic trials in Alzheimer’s diseaseNeurobiology of Aging, 2003
- Cerebrospinal fluid levels of total-tau, phospho-tau and Aβ42 predicts development of Alzheimer's disease in patients with mild cognitive impairmentActa Neurologica Scandinavica, 2003
- Tracking of Alzheimer's disease progression with cerebrospinal fluid tau protein phosphorylated at threonine 231Annals of Neurology, 2001
- CSF Phosphorylated Tau Protein and Mild Cognitive Impairment: A Prospective StudyExperimental Neurology, 2000
- Three-year follow-up of cerebrospinal fluid tau, β-amyloid 42 and 40 concentrations in Alzheimer's diseaseNeuroscience Letters, 2000
- Specific Hippocampal Volume Reductions in Individuals at Risk for Alzheimer’s DiseaseNeurobiology of Aging, 1997
- Distribution of Alzheimer‐type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's diseaseNeurology, 1992
- EARLY MARKER FOR ALZHEIMER'S DISEASE: THE ATROPHIC HIPPOCAMPUSThe Lancet, 1989